Groupama Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Groupama Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$93.9M	Buy	188,156 +22,259	+13%	+$9.86M	1.18%	24
2026 Q1	$74.1M	Buy	165,897 +2,753	+2%	+$1.28M	1.08%	31
2025 Q4	$74M	Buy	163,144 +119,763	+276%	+$51.6M	1.08%	24
2025 Q3	$17M	Sell	43,381 -17,916	-29%	-$7.49M	0.25%	65
2025 Q2	$27.1M	Buy	61,297 +9,364	+18%	+$4.32M	0.45%	48
2025 Q1	$25.6M	Buy	51,933 +8,454	+19%	+$3.94M	0.51%	48
2024 Q4	$17.4M	Buy	43,479 +9,149	+27%	+$4.24M	0.35%	60
2024 Q3	$12.8M	Buy	34,330 +3,739	+12%	+$1.8M	0.33%	62
2024 Q2	$14.3M	Buy	30,591 +20,033	+190%	+$8.7M	0.19%	77
2024 Q1	$12.2M	Sell	10,558 -14,481	-58%	-$6.12M	0.22%	83
2023 Q4	$10.2M	Buy	+25,039	New	+$9.25M	0.27%	71

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Groupama Asset Management's VRTX Position: Q2 2026 in Review

Groupama Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, buying an estimated $9.86M and bringing the position to 188,156 shares worth $93.9M. The position accounts for 1.18% of the portfolio, ranked #24.

Groupama Asset Management first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Groupama Asset Management held 188,156 shares of Vertex Pharmaceuticals worth $93.9M as of Q2 2026.
Groupama Asset Management bought 22,259 Vertex Pharmaceuticals shares in Q2 2026, an estimated $9.86M.
Vertex Pharmaceuticals made up 1.18% of Groupama Asset Management's portfolio in Q2 2026, its #24 holding.
Groupama Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Groupama Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.